Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Increases By 389.6%

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 151,300 shares, a growth of 389.6% from the November 15th total of 30,900 shares. Based on an average trading volume of 1,740,000 shares, the short-interest ratio is presently 0.1 days. Currently, 1.7% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “neutral” rating and issued a $7.00 price target on shares of Windtree Therapeutics in a research report on Wednesday, December 4th.

Windtree Therapeutics Price Performance

Shares of NASDAQ WINT traded down $0.01 during midday trading on Wednesday, reaching $0.36. 317,878 shares of the stock were exchanged, compared to its average volume of 803,454. Windtree Therapeutics has a 12 month low of $0.35 and a 12 month high of $14.75. The business has a 50-day simple moving average of $0.69 and a two-hundred day simple moving average of $3.65. The company has a market capitalization of $3.22 million, a price-to-earnings ratio of -0.02 and a beta of 0.54.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.